The price drop in weight-loss drugs Indian pharma can’t handle
Even though GLP-1 drugs have helped nearly 20 million people shed weight across the world since 2021, Indians had to wait until 2025 to get in on the action legally. To be fair, the country wasn’t entirely in the dark. Semaglutide—the molecule behind pharma giant Novo Nordisk’s blockbuster drugs Ozempic and Wegovy—was…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Daybreak
See all episodes →UPI is the trojan horse taking small banks into HDFC, Axis's credit-card empire
How India's rich are finding returns in the country's court backlog
Amazon’s quick-commerce win will be less about speed and more about Prime
Similar episodes from other shows
More like Daybreak →
Semaglutide Goes Generic: Big Pharma’s Moat Breaks
Weight Loss Just Got Easier in India?
Can India become the pharmacy for weight-loss drugs?
Mounjaro hits India, Bengal's Diamond Harbour Model, and Waqf Bill faces heat
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.